Erasca Q2 Loss Widens to $44M as R&D Costs Surge; Pipeline Timelines Updated
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca's Q2 net loss widened to $44.08 million from higher R&D spending on clinical trials and preclinical work. The company ended the quarter with $384 million in cash, bolstered by a $632 million July offering. Management now expects Phase 1 monotherapy expansion data for ERAS-0015 in H1 2027 and preliminary Phase 1 monotherapy data for ERAS-4001 in H2 2026. The updated timelines and cash runway guidance provide new visibility into the pipeline's progress and funding horizon.
At the time of this announcement, ERAS was trading at $18.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.